Search Results for: 19

— Gene Therapy Veteran to Enhance Company’s DNA-Based Therapeutic Development — ANN ARBOR, Mich., April 18, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Michael Kaleko, M.D., Ph.D., has joined the Company as Scientific Director. Dr. Kaleko has worked […]

— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported  financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics